Nothing Special   »   [go: up one dir, main page]

WO2008150010A1 - γ-セクレターゼの新規基質EphA4を利用したスクリーニング方法 - Google Patents

γ-セクレターゼの新規基質EphA4を利用したスクリーニング方法 Download PDF

Info

Publication number
WO2008150010A1
WO2008150010A1 PCT/JP2008/060567 JP2008060567W WO2008150010A1 WO 2008150010 A1 WO2008150010 A1 WO 2008150010A1 JP 2008060567 W JP2008060567 W JP 2008060567W WO 2008150010 A1 WO2008150010 A1 WO 2008150010A1
Authority
WO
WIPO (PCT)
Prior art keywords
epha4
secretase
screening method
method utilizing
novel substrate
Prior art date
Application number
PCT/JP2008/060567
Other languages
English (en)
French (fr)
Inventor
Eiji Inoue
Original Assignee
Eisai R & D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R & D Management Co., Ltd. filed Critical Eisai R & D Management Co., Ltd.
Priority to AT08765357T priority Critical patent/ATE546543T1/de
Priority to JP2009517923A priority patent/JP5511377B2/ja
Priority to EP08765357A priority patent/EP2166110B1/en
Publication of WO2008150010A1 publication Critical patent/WO2008150010A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

　本発明は、γ-セクレターゼによるEphA4のプロセシングに影響を与える化合物をスクリーニングする方法であって、以下のステップ： 　(i) 候補化合物の存在下および非存在下で、γ-セクレターゼまたはその生物学的に活性な断片を含む第１の生物学的組成物を、EphA4を含む第２の生物学的組成物と接触させ； 　(ii) 当該候補化合物の存在下と非存在下で、当該EphA4の開裂を測定し； 　(iii) γ-セクレターゼによる当該EphA4の開裂に影響を与える当該候補化合物を選択し；そして 　(iv) 前記(iii)で得られた候補化合物が、γ-セクレターゼによるEphA4のプロセシングに影響を与える化合物であると同定する、 　ことを含む、上記方法を提供する。
PCT/JP2008/060567 2007-06-08 2008-06-09 γ-セクレターゼの新規基質EphA4を利用したスクリーニング方法 WO2008150010A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AT08765357T ATE546543T1 (de) 2007-06-08 2008-06-09 Screening-verfahren mit verwendung des neuen substrats epha4 für gamma-sekretase
JP2009517923A JP5511377B2 (ja) 2007-06-08 2008-06-09 γ−セクレターゼの新規基質ＥｐｈＡ４を利用したスクリーニング方法
EP08765357A EP2166110B1 (en) 2007-06-08 2008-06-09 Screening method utilizing novel substrate epha4 for gamma-secretase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94268707P 2007-06-08 2007-06-08
US60/942,687 2007-06-08

Publications (1)

Publication Number Publication Date
WO2008150010A1 true WO2008150010A1 (ja) 2008-12-11

Family

ID=40093812

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/060567 WO2008150010A1 (ja) 2007-06-08 2008-06-09 γ-セクレターゼの新規基質EphA4を利用したスクリーニング方法

Country Status (5)

Country Link
US (2) US7910324B2 (ja)
EP (1) EP2166110B1 (ja)
JP (1) JP5511377B2 (ja)
AT (1) ATE546543T1 (ja)
WO (1) WO2008150010A1 (ja)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009069808A1 (ja) * 2007-11-30 2009-06-04 Eisai R & D Management Co., Ltd. 新規活性を有するEphA4ポリペプチドおよびその用途
WO2010141974A1 (en) * 2009-06-10 2010-12-16 The University Of Melbourne Therapeutic applications
US8137926B2 (en) 2007-06-08 2012-03-20 Eisai R&D Management Co., Ltd. Kit for assaying EphA4 processing by gamma-secretase
WO2012081502A1 (ja) 2010-12-17 2012-06-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法
WO2012147798A1 (ja) 2011-04-25 2012-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 EphA4細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
US8530181B2 (en) 2007-11-15 2013-09-10 Eisai R&D Management Co., Ltd. Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase
JP2019501112A (ja) * 2015-10-27 2019-01-17 ザ ユニバーシティー オブ クイーンズランド 治療の方法およびそのために有用な剤
US10428140B2 (en) 2015-09-08 2019-10-01 Eisai R&D Management Co., Ltd. Anti-EphA4 antibody
US10947313B2 (en) 2019-07-01 2021-03-16 Eisai R&D Management Co., Ltd. Anti-EphA4 antibody
WO2022138707A1 (ja) * 2020-12-24 2022-06-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 筋萎縮性側索硬化症の治療用医薬組成物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177623A4 (en) * 2007-07-19 2010-12-29 Eisai R&D Man Co Ltd SCREENING METHOD USING C-MET, A NEW SUBSTRATE FOR GAMMA SECRETASE
JPWO2009017234A1 (ja) * 2007-08-01 2010-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 γ−セクレターゼの新規基質ｃ−Ｒｅｔを利用したスクリーニング方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003169699A (ja) * 2001-12-10 2003-06-17 Japan Science & Technology Corp 特異的γプロテアーゼ阻害剤のスクリーニング方法
WO2005083086A2 (en) 2004-02-27 2005-09-09 Oncotherapy Science, Inc. Epha4 as therapeutic target of prc and pdaca
JP2006508653A (ja) * 2002-11-26 2006-03-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ノッチをベースとした、γ−セクレターゼの可溶性基質と、その利用法およびそれを利用した組成物
WO2006061660A1 (en) * 2004-12-09 2006-06-15 Merck Sharp & Dohme Limited Assay method

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020068361A1 (en) 1997-04-08 2002-06-06 Douglas Clary Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner
AU6887698A (en) 1997-04-08 1998-10-30 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US20060241074A1 (en) 2001-08-14 2006-10-26 The General Hospital Corporation Methods for treatment of pain
US20070026409A1 (en) 2001-08-14 2007-02-01 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
EP1478772A2 (en) 2001-08-14 2004-11-24 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
JP2004000060A (ja) 2002-05-31 2004-01-08 Otsuka Pharmaceut Co Ltd アミロイドβ産生に影響を与える化合物のスクリーニング方法
WO2005045028A1 (ja) 2003-11-10 2005-05-19 Osaka Industrial Promotion Organization セル・フリー・Ｎｏｔｃｈ切断分析方法及び薬剤スクリーニング方法
EP1662259A1 (en) 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
US20070051145A1 (en) * 2005-09-02 2007-03-08 Ez Trend Technology Co.,Ltd Electric lock
EP1947193A1 (en) 2007-01-17 2008-07-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Screening method for anti-diabetic compounds
ATE546543T1 (de) 2007-06-08 2012-03-15 Eisai R&D Man Co Ltd Screening-verfahren mit verwendung des neuen substrats epha4 für gamma-sekretase
EP2183598A1 (en) * 2007-07-13 2010-05-12 Elan Pharmaceuticals Inc. Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase
EP2177623A4 (en) * 2007-07-19 2010-12-29 Eisai R&D Man Co Ltd SCREENING METHOD USING C-MET, A NEW SUBSTRATE FOR GAMMA SECRETASE
US20090163594A1 (en) * 2007-10-31 2009-06-25 Elan Pharmaceuticals, Inc. Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
JP5508857B2 (ja) * 2007-11-30 2014-06-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規活性を有するＥｐｈＡ４ポリペプチドおよびその用途
US20100113415A1 (en) * 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003169699A (ja) * 2001-12-10 2003-06-17 Japan Science & Technology Corp 特異的γプロテアーゼ阻害剤のスクリーニング方法
JP2006508653A (ja) * 2002-11-26 2006-03-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ノッチをベースとした、γ−セクレターゼの可溶性基質と、その利用法およびそれを利用した組成物
WO2005083086A2 (en) 2004-02-27 2005-09-09 Oncotherapy Science, Inc. Epha4 as therapeutic target of prc and pdaca
WO2006061660A1 (en) * 2004-12-09 2006-06-15 Merck Sharp & Dohme Limited Assay method

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AOTO J. ET AL.: "Bidirectional ephrin/Eph signaling in synaptic functions", BRAIN RES., vol. 1184, 2007, pages 72 - 80, XP022364561 *
FOX G.M. ET AL.: "cDNA cloning and tissue distribution of five human EPH-like receptor protein-tyrosine kinases", ONCOGENE, vol. 10, no. 5, 1995, pages 897 - 905, XP000946743 *
MURAI KK; NGUYEN LN; IRIE F; YAMAGUCHI Y; PASQUALE EB: "Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling", NAT NEUROSCI., vol. 6, no. 2, February 2003 (2003-02-01), pages 153 - 60
SASTRE ET AL., EMBO REPORTS, vol. 2, 2001, pages 835 - 841
SAURA CA; CHOI SY; BEGLOPOULOS V; MALKANI S; ZHANG D; SHANKARANARAYANA RAO BS; CHATTARJI S; KELLEHER RJ 3RD; KANDEL ER; DUFF K: "Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age- dependent neurodegeneration", NEURON, vol. 42, no. 1, 8 April 2004 (2004-04-08), pages 23 - 36
YOKOTE ET AL., PROC. NATL. ACAD. SCI USA, vol. 102, 2005, pages 18866 - 18871

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137926B2 (en) 2007-06-08 2012-03-20 Eisai R&D Management Co., Ltd. Kit for assaying EphA4 processing by gamma-secretase
US8530181B2 (en) 2007-11-15 2013-09-10 Eisai R&D Management Co., Ltd. Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase
US7892769B2 (en) 2007-11-30 2011-02-22 Eisai R&D Management Co., Ltd. Processing of EphA4 polypeptide by γ-secretase activity
WO2009069808A1 (ja) * 2007-11-30 2009-06-04 Eisai R & D Management Co., Ltd. 新規活性を有するEphA4ポリペプチドおよびその用途
WO2010141974A1 (en) * 2009-06-10 2010-12-16 The University Of Melbourne Therapeutic applications
JP6059017B2 (ja) * 2010-12-17 2017-01-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラチナーゼによるＥｐｈＡ４の切断反応を指標としたスクリーニング方法
WO2012081502A1 (ja) 2010-12-17 2012-06-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法
US8865426B2 (en) 2010-12-17 2014-10-21 Eisai R&D Management Co., Ltd. Screening method using gelatinase-mediated EphA4 cleavage reaction as an indicator
WO2012147798A1 (ja) 2011-04-25 2012-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 EphA4細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
US9784751B2 (en) 2011-04-25 2017-10-10 Eisai R&D Management Co., Ltd. Method for detecting neurological disease associated with cognitive impairment by measuring EphA4 extracellular domain
US10428140B2 (en) 2015-09-08 2019-10-01 Eisai R&D Management Co., Ltd. Anti-EphA4 antibody
JP2019501112A (ja) * 2015-10-27 2019-01-17 ザ ユニバーシティー オブ クイーンズランド 治療の方法およびそのために有用な剤
US10947313B2 (en) 2019-07-01 2021-03-16 Eisai R&D Management Co., Ltd. Anti-EphA4 antibody
US11136400B2 (en) 2019-07-01 2021-10-05 Eisai R&D Management Co., Ltd. Anti-EphA4 antibody
WO2022138707A1 (ja) * 2020-12-24 2022-06-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 筋萎縮性側索硬化症の治療用医薬組成物

Also Published As

Publication number Publication date
JPWO2008150010A1 (ja) 2010-08-26
EP2166110A1 (en) 2010-03-24
ATE546543T1 (de) 2012-03-15
US20110111444A1 (en) 2011-05-12
EP2166110A4 (en) 2010-07-28
US8137926B2 (en) 2012-03-20
JP5511377B2 (ja) 2014-06-04
US7910324B2 (en) 2011-03-22
EP2166110B1 (en) 2012-02-22
US20090142788A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
WO2008150010A1 (ja) γ-セクレターゼの新規基質EphA4を利用したスクリーニング方法
WO2009011426A1 (ja) γ-セクレターゼの新規基質c-Metを利用したスクリーニング方法
WO2007035864A3 (en) Electrophoresis standards, methods and kits
WO2009073201A3 (en) Alternate labeling strategies for single molecule sequencing
WO2009064006A1 (ja) γ-セクレターゼの新規基質EphA7を利用したスクリーニング方法
HK1119244A1 (en) Detecting and predicting pre-eclampsia
WO2007120265A3 (en) Coded molecules for detecting target analytes
EA201071067A1 (ru) Микробиологический способ производства спирта
WO2005071096A3 (en) Derivatives of cephalosporin and clavulanic acid for detecting beta-lacamase in a sample
WO2007100506A3 (en) Mass tags for quantitative analyses
ATE515488T1 (de) Click-chemie zur herstellung von reportermolekülen
WO2008077642A3 (en) Detection of gene expression in cells by scanning fcs
EA200701742A1 (ru) Способы получения сиропа
WO2007087339A3 (en) Multiplexed analyte quantitation by two-dimensional planar electrochromatography
WO2005005977A3 (en) Fluorescent phospholipase assays and compositions
WO2008049930A3 (en) A method for profiling kinase inhibitors
WO2005106036A3 (en) Methods and compositions for assaying analytes
MX336093B (es) Deteccion y enumeracion de microorganismos.
GB0615302D0 (en) Assay Method For The Detection Of Viable Microbial Cells In A Sample
DK2118666T3 (da) Fremgangsmåde til normalisering af koncentrationen af analytter i en urinprøve
WO2009017234A1 (ja) γ-セクレターゼの新規基質c-Retを利用したスクリーニング方法
MY159867A (en) Detection and enumeration of microorganisms
WO2008087895A1 (ja) 高密度リポ蛋白中コレステロール測定方法およびその試薬
WO2008034622A3 (en) A method of detecting and/or quantifying expression of a target protein candidate in a cell, and a method of identifying a target protein of a small molecule modulator
WO2006129036A3 (fr) Biomarqueur a emission luminescente

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08765357

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009517923

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008765357

Country of ref document: EP